ACADIA is committed to the discovery, development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system (CNS) disorders. Our clinical and preclinical programs all emanate from internal discoveries and are rooted in our scientific heritage and strength in CNS research.
As part of our strategy, we selectively pursue strategic collaborations to advance and maximize the commercial potential of our pipeline. In areas where our products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we plan to commercialize our product candidates in the United States. In therapeutic areas that require large specialty or primary care sales forces, we may choose to conduct commercialization through, or in collaboration with, partners. We plan to commercialize our products in markets outside of the United States by establishing one or more strategic alliances.
To further explore partnering opportunities with ACADIA, please contact us at email@example.com.
ACADIA has formed two ongoing separate collaborations with Allergan focused in the areas of pain and ophthalmology:
The first collaboration has resulted in the discovery of alpha adrenergic drug candidates for the treatment of chronic pain.
In the second collaboration, Allergan and ACADIA are focused on the development and commercialization of selective muscarinic drugs for the treatment of glaucoma.back to top